News Report · Pulmonology

FDA Approves Cytisinicline for Smoking Cessation: 30.3% Continuous Abstinence Rate in ORCA Trials

June 09, 2026

Clinical Perspective

Cytisinicline represents a new option for smoking cessation, demonstrating promising efficacy in achieving continuous abstinence rates significantly higher than placebo in clinical trials.

Dr. Nikhil Chatterjee · Pulmonology

Cytisinicline reduced continuous abstinence rates by 30.3% versus 18.9% in placebo in adults with nicotine dependence in the ORCA-1 and ORCA-2 trials (HR not available) ^[1].

Clinical Context

Nicotine dependence is a significant public health issue, affecting millions of adults in the United States and contributing to various health problems, including cardiovascular diseases and respiratory disorders. Current treatments for smoking cessation include nicotine replacement therapies and prescription medications like varenicline and bupropion, which aim to alleviate withdrawal symptoms and cravings. However, many patients struggle to achieve long-term abstinence, highlighting a gap in effective treatment options. The approval of cytisinicline, a natural alkaloid and partial nicotinic agonist, represents a potential advancement in pharmacotherapy for smoking cessation, as evaluated in the ORCA trials.

Key Findings

The ORCA-1 and ORCA-2 trials showed cytisinicline reduced continuous abstinence rates by 30.3% versus placebo (HR not available) ^[1].
The trials enrolled 1,500 adults with nicotine dependence ^[1].
Event rates: 30.3% for cytisinicline vs 18.9% for placebo ^[1].
The primary endpoint was continuous abstinence from smoking for at least 6 months ^[1].
Secondary endpoint results demonstrated significant improvements in withdrawal symptoms and cravings with cytisinicline compared to placebo ^[1].
Cytisinicline is administered at a dose of 3 mg orally three times daily ^[1]. Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Nausea reported with cytisinicline — exact frequency not available in public source summary ^[1].
Vomiting reported — exact frequency not available in public source summary ^[1].
Insomnia reported ^[1].
Dizziness reported — monitor during treatment ^[1].
Hyperhidrosis reported ^[1].
Complete adverse event profile available in the full prescribing information for cytisinicline.

What This Means for Clinical Practice

Cytisinicline is indicated for adults with nicotine dependence based on criteria from the ORCA trials. The data supports a continuous abstinence rate of 30.3%, suggesting it may be an effective option for patients struggling with smoking cessation. How will clinicians integrate cytisinicline into existing smoking cessation protocols?

Study Design

The ORCA-1 and ORCA-2 trials were multicenter, randomized, double-blind, placebo-controlled studies involving 1,500 adults diagnosed with nicotine dependence. The primary endpoint was continuous abstinence from smoking for at least 6 months, with follow-up durations extending up to one year. The studies were funded by Achieve Life Sciences, and key limitations included the reliance on self-reported smoking status and potential biases in participant selection. Further data on long-term efficacy and safety is still pending.

FAQ

What is cytisinicline approved for?

Cytisinicline is approved for smoking cessation in adults based on the ORCA trials, which demonstrated a continuous abstinence rate of 30.3% compared to placebo.

How does cytisinicline work?

Cytisinicline is a partial nicotinic agonist that mimics the action of nicotine, helping to reduce withdrawal symptoms and cravings associated with nicotine dependence.

What is the recommended dose of cytisinicline?

Cytisinicline is administered at a dose of 3 mg orally three times daily. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for cytisinicline.

What are the most common side effects of cytisinicline?

Common side effects include nausea, vomiting, insomnia, dizziness, and hyperhidrosis. Exact frequencies of these side effects are not available in public source summaries.

FDA Approves Cytisinicline for Smoking Cessation: 30.3% Continuous Abstinence Rate in ORCA Trials

FDA Approves Cytisinicline for Smoking Cessation: 30.3% Continuous Abstinence Rate in ORCA Trials

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly clinical updates for Pulmonology in your inbox.

Related Clinical Updates

Asthma Triple Inhaler Therapy: Patient Selection Criteria for Trimbow, Trelegy, and Breztri

FDA Approves Tezepelumab for Severe Asthma: 52% Exacerbation Reduction in NAVIGATOR Trial

Depemokimab Shows Promise in Severe Eosinophilic Asthma: Annual Injection vs Mepolizumab and Benralizumab

Verified HCP Portal